Abstract
Background: Some former retrospective studies have suggested that patients with Ewing's sarcoma might have a very high risk for developing secondary sarcomas if treated with radiotherapy. We have evaluated the risk of second malignancies (SM) in patients treated in the German Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Materials and methods: From January 1981 through June 1991, a total number of 674 patients was registered in the two multicentric Ewing's sarcoma trials CESS 81 (1981 through 1985) and CESS 86 (1986 through June 1991). The systemic treatment consisted in both studies of a four-drug-chemotherapy (VACA= vincristine, actinomycin D, cyclophosphamide and adriamycin; or VAIA= vincristine, actinomycin D, ifosfamide and adriamycin) and a total number of four courses, each lasting nine weeks, was recommended by the protocol. Local therapy was either complete surgery or surgery plus postoperative radiotherapy with 36-46Gy or definitive radiotherapy with 46 to 60Gy. The median follow-up at the time of this analysis was 7 years, the maximum follow-up 16 years. Results: Eight patients developed a SM, 4 were acute myelogenic leucemias, three sarcomas and one benign neurinoma. One of the sarcomas was considered as radiation-induced because of its location in the former radiation field. The interval
More>>
Citation Formats
Ahrens, Susanne, Dunst, Juergen, Ruebe, Christian, Paulussen, Michael, Hoffmann, Christine, and Juergens, Herbert.
Second malignancies after treatment for Ewing's sarcoma.
United States: N. p.,
1997.
Web.
doi:10.1016/S0360-3016(97)80573-1.
Ahrens, Susanne, Dunst, Juergen, Ruebe, Christian, Paulussen, Michael, Hoffmann, Christine, & Juergens, Herbert.
Second malignancies after treatment for Ewing's sarcoma.
United States.
https://doi.org/10.1016/S0360-3016(97)80573-1
Ahrens, Susanne, Dunst, Juergen, Ruebe, Christian, Paulussen, Michael, Hoffmann, Christine, and Juergens, Herbert.
1997.
"Second malignancies after treatment for Ewing's sarcoma."
United States.
https://doi.org/10.1016/S0360-3016(97)80573-1.
@misc{etde_20393499,
title = {Second malignancies after treatment for Ewing's sarcoma}
author = {Ahrens, Susanne, Dunst, Juergen, Ruebe, Christian, Paulussen, Michael, Hoffmann, Christine, and Juergens, Herbert}
abstractNote = {Background: Some former retrospective studies have suggested that patients with Ewing's sarcoma might have a very high risk for developing secondary sarcomas if treated with radiotherapy. We have evaluated the risk of second malignancies (SM) in patients treated in the German Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Materials and methods: From January 1981 through June 1991, a total number of 674 patients was registered in the two multicentric Ewing's sarcoma trials CESS 81 (1981 through 1985) and CESS 86 (1986 through June 1991). The systemic treatment consisted in both studies of a four-drug-chemotherapy (VACA= vincristine, actinomycin D, cyclophosphamide and adriamycin; or VAIA= vincristine, actinomycin D, ifosfamide and adriamycin) and a total number of four courses, each lasting nine weeks, was recommended by the protocol. Local therapy was either complete surgery or surgery plus postoperative radiotherapy with 36-46Gy or definitive radiotherapy with 46 to 60Gy. The median follow-up at the time of this analysis was 7 years, the maximum follow-up 16 years. Results: Eight patients developed a SM, 4 were acute myelogenic leucemias, three sarcomas and one benign neurinoma. One of the sarcomas was considered as radiation-induced because of its location in the former radiation field. The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17 to 78 months for the four AMLs and 82 to 136 months for the three sarcomas. All solid second tumors occurred in irradiated patients. The cumulative risk of a SM is given in table 1. Three patients (all with AML) died of their SM, the other five were salvage by subsequent treatment and are in clinical remission with a median follow-up of 1 to 10 years. Conclusions: The risk of leukemia after treatment for Ewing's sarcoma is probably low in the range of 1-2% or less and accounts for about 1% of all deaths. There was no risk of solid tumors in surgically treated patients. Irradiated patients seem to be at low risk for solid tumors within the first ten years after treatment but have a 5%-risk of developing any solid tumor after 15 years. However, there have been no deaths due to secondary sarcomas up to now.}
doi = {10.1016/S0360-3016(97)80573-1}
journal = []
issue = {2,suppl.1}
volume = {39}
journal type = {AC}
place = {United States}
year = {1997}
month = {Jul}
}
title = {Second malignancies after treatment for Ewing's sarcoma}
author = {Ahrens, Susanne, Dunst, Juergen, Ruebe, Christian, Paulussen, Michael, Hoffmann, Christine, and Juergens, Herbert}
abstractNote = {Background: Some former retrospective studies have suggested that patients with Ewing's sarcoma might have a very high risk for developing secondary sarcomas if treated with radiotherapy. We have evaluated the risk of second malignancies (SM) in patients treated in the German Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Materials and methods: From January 1981 through June 1991, a total number of 674 patients was registered in the two multicentric Ewing's sarcoma trials CESS 81 (1981 through 1985) and CESS 86 (1986 through June 1991). The systemic treatment consisted in both studies of a four-drug-chemotherapy (VACA= vincristine, actinomycin D, cyclophosphamide and adriamycin; or VAIA= vincristine, actinomycin D, ifosfamide and adriamycin) and a total number of four courses, each lasting nine weeks, was recommended by the protocol. Local therapy was either complete surgery or surgery plus postoperative radiotherapy with 36-46Gy or definitive radiotherapy with 46 to 60Gy. The median follow-up at the time of this analysis was 7 years, the maximum follow-up 16 years. Results: Eight patients developed a SM, 4 were acute myelogenic leucemias, three sarcomas and one benign neurinoma. One of the sarcomas was considered as radiation-induced because of its location in the former radiation field. The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17 to 78 months for the four AMLs and 82 to 136 months for the three sarcomas. All solid second tumors occurred in irradiated patients. The cumulative risk of a SM is given in table 1. Three patients (all with AML) died of their SM, the other five were salvage by subsequent treatment and are in clinical remission with a median follow-up of 1 to 10 years. Conclusions: The risk of leukemia after treatment for Ewing's sarcoma is probably low in the range of 1-2% or less and accounts for about 1% of all deaths. There was no risk of solid tumors in surgically treated patients. Irradiated patients seem to be at low risk for solid tumors within the first ten years after treatment but have a 5%-risk of developing any solid tumor after 15 years. However, there have been no deaths due to secondary sarcomas up to now.}
doi = {10.1016/S0360-3016(97)80573-1}
journal = []
issue = {2,suppl.1}
volume = {39}
journal type = {AC}
place = {United States}
year = {1997}
month = {Jul}
}